Glenmark Units Sue Astellas, Triax, Other Drug Makers In U.S. Court
This article was originally published in PharmAsia News
Glenmark Generics USA said it is suing Triax Pharmaceuticals and two Astellas Pharma units to enforce a six-month exclusivity agreement it has with them for its Hydrocortisone Butyrate Cream for skin inflammation relief.
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.
Infogram: OTC firms should start thinking about post-COVID-19 business strategy, SEMPORA Consulting GmbH suggests, based on a recent survey on the impact of the coronavirus on German OTC companies.